Vyant Bio Inc. (NASDAQ: VYNT): Leading a New Biotech Move to Combat Diseases Affecting the Nervous System

Vyant Bio Inc. (NASDAQ: VYNT): Leading a New Biotech Move to Combat Diseases Affecting the Nervous System

Biotechnology companies such as Biogen Inc. BIIB,  Alector Inc. ALEC, Amylyx Pharmaceuticals Inc. AMLX and Addex Therapeutics Ltd. ADXN have heavily invested in developing therapies for neurodegenerative disorders, often without a cure for these conditions, and exceedingly difficult symptoms for patients.

Another biotech company, Vyant Bio, Inc. VYNT, is leading the way in developing a new strategy to battle complex neurodevelopmental and neurodegenerative disorders. The Company has established a central nervous system (CNS) drug discovery platform that combines patient-derived organoid models of brain disease, biology at scale, and machine learning, to elucidate disease pathophysiology and identify and validate drug targets for rare CNS genetic disorders. Using patient-derived induced stem cells, a homogeneous cortical organoid platform can efficiently screen large compound libraries in a highly reproducible fashion.

Vyant Bio has used its drug discovery platform to discover and develop therapeutics to treat neurodevelopmental and neurodegenerative diseases, including Rett syndrome, CDKL5 deficiency disorders, and Parkinson's disease.

The Company says it possesses a deep expertise and a global presence in drug discovery, human and data biology, and data science-driven proprietary discovery engines focused on efficiently discovering novel therapeutics for neurological diseases.

Working To Solve Rett Syndrome In Females

Vyant Bio identified a clinical candidate for Rett syndrome by rescuing a disease phenotype in vitro using proprietary high-throughput screening technology and the application of its proprietary machine learning algorithms.

Rett syndrome is a progressive neurodevelopmental disorder that almost exclusively affects females. According to the National Institute of Neurological Disorders and Stroke, it affects 1 in 10,000 to 15,000 live female births and all racial and ethnic groups worldwide.

Infants with Rett syndrome generally develop normally for about seven to 18 months before losing previously acquired developmental skills such as using the hands and the ability to communicate. Some children also have slowing head growth and develop autistic-like behaviors, breathing irregularities, feeding and swallowing difficulties, growth retardation, and seizures.

The course and severity of Rett syndrome are determined by the location, type, and severity of the CpG binding protein 2 or MECP2 gene and the process of random X-inactivation. Because of this, two girls of the same age with the same mutation can appear significantly different.

Vyant Bio sees its work on Rett syndrome, an estimated $1.5 billion market opportunity, as the precursor to other drug discovery pursuits in broader categories such as Parkinson’s disease. The Company is preparing for a proof of concept clinical trial in an adult population expected to begin in early 2023 in its Rett syndrome research.

Vyant Bio’s approach to drug discovery integrates human-derived biology with artificial intelligence and machine learning technologies to de-risk candidate selection. The Company hopes to improve the potential effectiveness of drugs discovered earlier in the development cycle.

The goal is to shift to more efficient methods because the widely used models for predicting safe and effective drugs have underperformed, as evidenced by the significant time and cost of bringing novel medicines to market.

Vyant Bio reported ample near-term liquidity, with a cash balance of $11.7 million, along with future proceeds from the sale of a non-core subsidiary, an equity line of credit in place, and an at-the-market financing facility, sufficient to fund operations over the next 18 months.  

Vyant Bio hopes that by combining sophisticated data science capabilities with highly functional human cell-derived disease models, it will leverage its current ability to screen and test therapeutic candidates and accelerate into clinical trials with drugs with a higher probability of being effective.

For more information on Vyant Bio Inc., visit www.vyantbio.com.

The preceding/following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and Skyline Corporate Communications Group, LLC, a financial partner of Benzinga. This article/video is a paid sponsorship by investor relations agency Skyline Corporate Communications Group, LLC, which is paid by Vyant Bio Inc. VYNT  for providing investor relations and corporate communications services relating to the Company’s securities. Please see Skyline's 17(b) Disclaimer and Disclosure Statement here: https://skylineccg.com/disclosures/

Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. 

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Photo by National Cancer Institute on Unsplash

Posted In: Partner ContentVyant Bio Inc.BiotechPenny StocksSmall CapGeneral